Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab after SBRT for unresectable stage I/II node-negative NSCLC
CTR20210045Phase 3Active
- Sponsor
- MedImmune
- Start
- Feb 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, osimertinib in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Started Feb 2021; status: active.
02
Drugs
durvalumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210045.